Dr. Shahe K. Garabedian, MD

Dr. Garabedian practices at Cardiovascular Consultants Medical Group in Valencia, California.

Dr. Garabedian's NPI, 1841313772, was assigned on April 7, 2007. Dr. Garabedian graduated from Georgetown University School Of Medicine in 2004. Dr. Garabedian holds California license A103461.

Dr. Garabedian's primary practice is Cardiovascular Consultants Medical Group, at 23929 McBean Pkwy, Valencia, CA 91355 in Los Angeles County. The practice phone is (661) 259-1534.

Dr. Garabedian's primary practice is Cardiovascular Consultants Medical Group in Valencia, California. Dr. Garabedian is also affiliated with Henry Mayo Newhall Hospital. The medical group on file is Cardiovascular Consultants Medical Group. Dmand AI also links Dr. Garabedian to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Garabedian practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Garabedian's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Garabedian is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Garabedian's licenses on file in 3 states: California, District of Columbia and Virginia.

Dmand AI lists aneurysm, angioplasty, atrial fibrillation and flutter, cardiac catheterization, cardiomyopathy, chronic embolism thrombosis, chronic hypertension and coronary artery disease among the conditions Dr. Garabedian treats.

CMS data shows 4,409 Medicare services from Dr. Garabedian across 23 procedure codes in 2024, for 1,535 Medicare patients. Medicare paid $350,672 for them.

CMS counts 1,535 Medicare patients who saw Dr. Garabedian in 2024. The largest group is 75 to 84, with 581 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Garabedian's median patient age at 71, with 50% women.

In 2024, Dr. Garabedian wrote 3,443 Medicare Part D claims for 567 patients. 76% of them were for generic drugs. CMS names the drug for 3,212 of them, across 52 drugs with 11 or more claims each, at $887,623 in total drug cost. In 2023, CMS named 3,316 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Garabedian for performance year 2024, reported individually. CMS lists Dr. Garabedian as offering telehealth. CMS counts 32 procedures of varicose vein removal by Dr. Garabedian, more than 66% of the clinicians it reports for that procedure.

CMS Open Payments shows 423 general payments to Dr. Garabedian from 38 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. Abbott Laboratories paid the most, $1,742.

Dmand AI lists 2 awards for Dr. Garabedian, most recently CMS Stage 1 EHR in 2013.

Dr. Garabedian graduated from Georgetown University School Of Medicine in 2004. Dr. Garabedian is a member of ACC.

Dr. Garabedian is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.